Abstract
Background: Adenoid cystic carcinoma (ACC) are more common in the minor salivary glands (MiSGs) than the major salivary glands, and are characterized by slow tumor progression and frequently local recurrence. The main treatment option is surgery followed by combined radiotherapy. Methods: A retrospective analysis contained 67 patients with ACC of MiSGs in the oral cavity who underwent surgery followed by radiotherapy. The median cumulative IMRT dose was 50 Gy followed by 24 Gy for carbon ion (C12) boost. Median follow-up was 40 months. Results: Median 5-years overall survival (OS), progression-free survival (PFS) and local disease-free survival (LDFS) rates were 85.5%, 57.4% and 74.9%. Median time until progression was detected was 32 months (range: 2–205 months). Early grade ≥3 mucositis, dermatitis, and dysphagia were detected in 52.2%, 7.5% and 11.9% respectively. Besides common toxicities, two patients (3.0%) developed grade 3 toxicities with osteoradionecrosis of the jaw after 18 and 66 months. Higher-grade late toxicity (CTCAE grade 4) was not detected. No treatment-related death was detected. Conclusions: Our results demonstrate that postoperative combined radiotherapy with IMRT plus C12 boost seems to be a feasible and effective treatment method in ACC of MiSGs in the oral cavity, with good control and survival rates and adequate toxicity.
Highlights
Adenoid cystic carcinomas (ACCs) of the head and neck are located in the major salivary glands (MaSgs) and in the minor salivary glands (MiSGs)
ACCs are characterized by slow tumor progression associated with pain due to the predisposition of perineural invasion
Mean patient age is the middle and older years [5], and ACCs have a tendency for local recurrence and distant metastases
Summary
Adenoid cystic carcinomas (ACCs) of the head and neck are located in the major salivary glands (MaSgs) and in the minor salivary glands (MiSGs). Mean patient age is the middle and older years [5], and ACCs have a tendency for local recurrence and distant metastases. Distant metastases occur in 40–60% of patients, especially in late-stage disease [3,7,8,9]. The standard treatment strategy for ACCs is radical resection followed by adjuvant high-dose radiotherapy, especially in advanced disease (T3–4) and positive resection margin (R1–2) [10,11]. Adenoid cystic carcinoma (ACC) are more common in the minor salivary glands (MiSGs) than the major salivary glands, and are characterized by slow tumor progression and frequently local recurrence. The main treatment option is surgery followed by combined radiotherapy
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
